Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
News|Articles|December 2, 2020
- Pharmaceutical Technology-12-02-2020
- Volume 44
- Issue 12
Remote Particle Counter
The IsoAir Pro-E Remote Particle Counter by Particle Measuring Systems works to streamline cleanroom monitoring while complying with global regulations.
The IsoAir Pro-E Remote Particle Counter by Particle Measuring Systems works to streamline cleanroom monitoring while complying with global regulations. The device features a 316 L, liquid resistant stainless-steel enclosure and a built-in vacuum for use with the Vaporized Hydrogen Peroxide (VHP) process. Use of Power over Ethernet and an internal blower allow for minimal external connections and supporting equipment.
Additionally, the instrument stores sensor data, such as IP address, in a quick release mounting bracket, which shortens the unit installation time after calibration or servicing.
Articles in this issue
almost 6 years ago
Can Pharma Quality Go High Tech?almost 6 years ago
HPAPI Complexity Prompts New Delivery Mechanismsalmost 6 years ago
Modular Processes and Facilities Enable Flexible Vaccine Manufacturingalmost 6 years ago
Nitrosamine Impurities in Medicinal Productsalmost 6 years ago
USP, COVID-19, and Plans for the Futurealmost 6 years ago
EDQM Combats COVID-19 and Makes Plans for Futurealmost 6 years ago
Complying with Lab Data Integrity Practices During COVID-19almost 6 years ago
E-beam Process Could Offset Sterilization Constraintsalmost 6 years ago
Is the Packaging Supply Chain Ready?Related to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
5